Quoin Pharmaceuticals (QNRX) Price & Analysis

Q: What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $54.95 in the past 12 months.

Q: What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is $4.26M.

Q: When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

Q: How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$6.28 earnings per share for the quarter, beating the consensus estimate of -$6.82 by $0.54.

Q: Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

Q: What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -5.25.

Q: How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 588,167 shares outstanding.

Q: What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -$6.28 in its last earnings report, beating expectations of -$6.82. Following the earnings report the stock price went down -6.242%.

Q: Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in QNRX

Compare

331 Followers

QNRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.01 - $54.95

Previous CloseN/A

Volume155.80K

Average Volume (3M)4.33K

Market Cap

$4.26M

Enterprise Value-$11.42M

Total Cash (Recent Filing)$11.55M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.34

Next Earnings

Nov 06, 2025

EPS Estimate

-5.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.28

Shares Outstanding588,167

10 Day Avg. Volume5,358

30 Day Avg. Volume4,335

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)<0.01

Price to Sales (P/S)0.00

P/FCF Ratio-0.01

Enterprise Value/Market Cap-2.68

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit458.55

Enterprise Value/Ebitda1.63

Forecast

1Y Price Target

$70.00

Price Target Upside913.02% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Efficacy And SafetyConsistent positive data from QRX003 trials, including skin clearing and symptom reduction, supports its potential efficacy and safe tolerability in treating Netherton Syndrome.

FDA Review ProcessThe FDA has granted QRX003 Rare Pediatric Disease Designation, which can expedite its review process and increase the likelihood of approval.

Market OpportunityQRX003's potential approval could provide Quoin Pharmaceuticals with a significant market opportunity due to the lack of existing treatments for Netherton Syndrome.

Bears Say

Chronic Therapy RequirementQRX003 may likely be required as a chronic therapy and does exhibit a clinical effect on patients.

Post-Discontinuation DataUpdated data showed that 4 weeks post-discontinuation of therapy, the patients’ symptom and disease severity scores returned essentially to baseline levels.

Stock Price ConcernsThe shares are trading down ~25% as some investors may be concerned that QRX003 did not maintain symptom relief durability or 'cure' patients.

Quoin Pharmaceuticals News

Quoin Pharmaceuticals reports Q2 EPS ($6.28) vs ($13.68) last year

“Second quarter of 2025 was one of the most impactful in Quoin’s history, marked by meaningful progress on...

1d ago

QNRX

Quoin Pharmaceuticals provides update on its development product portfolio

Quoin Pharmaceuticals (QNRX) provided an updated overview of its development product portfolio. The company’s lead product, QRX003 for...

10d ago

QNRX

Quoin Pharmaceuticals Reports Q2 2025 Financial Results

Quoin Pharmaceuticals Ltd ( ($QNRX) ) has released its Q2 earnings. Here is a breakdown of the information...

12h ago

QNRX

Buy Rating for Quoin Pharmaceuticals: Promising Developments in Netherton Syndrome Treatment and Strategic Regulatory Advantages

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals, with a price target of...

8d ago

QNRX

Quoin Pharmaceuticals CFO Departure Announcement

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an announcement. On July 3, 2025, Quoin Pharmaceuticals Ltd. announced that...

1M ago

QNRX

Quoin Pharmaceuticals releases new ‘NETHERTON NOW’ video

Quoin Pharmaceuticals (QNRX) announced the release of a new episode in its NETHERTON NOW video series. The episode...

1M ago

QNRX

Quoin Pharmaceuticals Receives FDA Rare Disease Designation

Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. On June 24, 2025, Quoin Pharmaceuticals announced that the...

1M ago

QNRX

Quoin Pharmaceuticals announces FDA granted RPD designation for QRX003

Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease, RPD,...

2M ago

QNRX

Quoin Pharmaceuticals Updates Shareholder Proposal Deadlines

The latest update is out from Quoin Pharmaceuticals ( ($QNRX) ). Quoin Pharmaceuticals Ltd. has announced that its...

2M ago

QNRX

Quoin Pharmaceuticals Approves Executive Cash Bonuses

Quoin Pharmaceuticals ( ($QNRX) ) has issued an update. On May 29, 2025, Quoin Pharmaceuticals Ltd.’s Compensation Committee...

2M ago

QNRX

Quoin Pharmaceuticals Receives FDA Clearance for New Study

Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. On May 22, 2025, Quoin Pharmaceuticals announced it received...

3M ago

QNRX

Quoin announces FDA clearance to initiate second whole body QRX003 NS study

Quoin Pharmaceuticals (QNRX) announces FDA clearance to initiate a second Netherton Syndrome, NS, pivotal clinical study CL-QRX003-002 for...

3M ago

QNRX

Quoin Pharmaceuticals’ QRX003 Gains Orphan Drug Status

The latest announcement is out from Quoin Pharmaceuticals ( ($QNRX) ). On May 20, 2025, Quoin Pharmaceuticals announced...

3M ago

QNRX

Quoin Pharmaceuticals announces EMA grants ODD for QRX003

Quoin Pharmaceuticals (QNRX) announces that it has been granted Orphan Drug Designation, ODD, in Europe by the European...

3M ago

QNRX

QNRX FAQ

What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $54.95 in the past 12 months.

What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is $4.26M.

When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$6.28 earnings per share for the quarter, beating the consensus estimate of -$6.82 by $0.54.

Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -5.25.

How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 588,167 shares outstanding.

What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -$6.28 in its last earnings report, beating expectations of -$6.82. Following the earnings report the stock price went down -6.242%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in QNRX

Company Description

Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Quoin Pharmaceuticals (QNRX) Earnings & Revenues

Historic Earnings Reports

QNRX Stock 12 Month Forecast

Average Price Target

$70.00

▲(913.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","190":"$190","51.25":"$51.3","97.5":"$97.5","143.75":"$143.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,51.25,97.5,143.75,190],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,11.68,16.54,21.400000000000002,26.26,31.12,35.980000000000004,40.84,45.7,50.56,55.42,60.28,65.14000000000001,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,11.68,16.54,21.400000000000002,26.26,31.12,35.980000000000004,40.84,45.7,50.56,55.42,60.28,65.14000000000001,{"y":70,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.82,11.68,16.54,21.400000000000002,26.26,31.12,35.980000000000004,40.84,45.7,50.56,55.42,60.28,65.14000000000001,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":189,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.31,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.77,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >